Barker Juliet N, Wagner John E
Department of Medicine, Blood and Marrow Transplant Program of the University of Minnesota School of Medicine, University of Minnesota, MMC 480 UMHC, 420 Delaware Street, SE, Minneapolis, MN 55455, USA.
Crit Rev Oncol Hematol. 2003 Oct;48(1):35-43. doi: 10.1016/s1040-8428(03)00092-1.
As a source of hematopoietic stem cells (HSCs), umbilical cord blood (UCB) has the advantages of speed of availability, tolerance of 1-2 antigen HLA mismatch, and a low incidence of severe GVHD. Thus, UCB represents a highly convenient HSC source that may significantly extend the HSC donor pool. UCB transplantation (UCBT) has become a standard practice in the treatment of pediatric malignancies. Now, UCBT is being investigated in adults using both conventional and non-myeloablative preparative regimens. As graft cell dose is the major factor determining hematopoietic recovery and survival in URD UCBT, methods to increase cell dose such as multiple-unit transplant and ex vivo expansion are being pursued. This review outlines the current status of UCBT with emphasis on current and future innovations.
作为造血干细胞（HSCs）的来源，脐带血（UCB）具有获取速度快、可耐受1-2个抗原HLA错配以及严重移植物抗宿主病（GVHD）发生率低等优点。因此，脐带血是一种非常便利的造血干细胞来源，可显著扩大造血干细胞供者库。脐带血移植（UCBT）已成为治疗儿童恶性肿瘤的标准方法。目前，正在使用传统和非清髓性预处理方案对成人进行脐带血移植研究。由于移植物细胞剂量是无关供者脐带血移植中决定造血恢复和生存的主要因素，因此正在探索增加细胞剂量的方法，如多单位移植和体外扩增。本综述概述了脐带血移植的现状，重点介绍了当前和未来的创新成果。
